Core Viewpoint - The company is committed to enhancing quality and efficiency while ensuring shareholder returns through a comprehensive action plan for 2025, focusing on core business development, international expansion, and effective governance [2][3]. Group 1: Business Development - The company has deepened its focus on the orthopedic medical device sector, emphasizing original innovation and product development to enhance core competitiveness [2]. - The company achieved a net profit attributable to shareholders of approximately 36.6 million yuan, representing a year-on-year increase of 2,083.64%, and a significant recovery from a previous loss [3]. - The company plans to continue developing innovative therapies and products, leveraging national policies that encourage domestic innovation in medical devices [3]. Group 2: International Expansion - The company has made significant progress in its international business, successfully entering the European and American markets with its Zeus spinal fixation system [4]. - Implanet, a subsidiary, reported revenue of 5.81 million euros in the first half of 2025, a year-on-year increase of 41.1%, with a remarkable 444% growth in the U.S. market in the second quarter [4]. Group 3: Strategic Partnerships and Acquisitions - The company completed the acquisition of the remaining equity in Beijing Waterwood Tianpeng Medical Technology Co., making it a wholly-owned subsidiary, and established a joint venture with a South Korean company to develop innovative biomedical materials [5]. - The introduction of Implanet's JAZZ system into the domestic market enhances the company's product line and competitive advantage in spinal surgery [5]. Group 4: Governance and Shareholder Returns - The company has implemented a stock incentive plan to attract and retain talent, aligning the interests of shareholders and management [7]. - A sustainable dividend strategy has been established, with a cash dividend of 0.042 yuan per share distributed to shareholders [8]. - The company is committed to optimizing its shareholder return mechanism and ensuring a balance between business growth and shareholder returns [9]. Group 5: Investor Relations and Communication - The company has enhanced its investor communication channels, conducting numerous disclosures and hosting events to engage with investors [10]. - Future plans include improving the clarity and transparency of information disclosures to ensure investors are well-informed about the company's operations and strategies [10]. Group 6: Compliance and Risk Management - The company has restructured its governance framework by abolishing the supervisory board and enhancing the roles of various committees to ensure effective oversight and compliance [11]. - Continuous training and communication efforts are in place to strengthen compliance awareness among key personnel [12].

Core Viewpoint - The company has announced its 2025 "Quality Improvement and Efficiency Enhancement" action plan, building on the achievements of the 2024 plan to optimize operations and governance while enhancing shareholder value [1]. Group 1: Business Strategy and Development - The company focuses on deepening its core business in orthopedic medical devices, emphasizing original innovation and increasing R&D investment to enhance competitiveness [1][2]. - In 2024, the company faced a significant decline in net profit, down 88% to 11.47 million yuan, primarily due to the impact of centralized procurement on spinal product sales [1]. - The company increased its R&D investment to 84.29 million yuan, a 29.24% year-on-year increase, representing 18.58% of total revenue, up 4.41 percentage points from the previous year [1]. Group 2: International Expansion - The company aims to expand its international business, leveraging its acquisition of Implanet to enhance brand recognition and market presence in developed countries [3][4]. - The JAZZ Spinal System from Implanet received FDA510(k) certification and began sales in the U.S. by the end of 2024, further enriching the company's international product line [3]. Group 3: Product Innovation and Technology - The company is advancing the development of new materials and intelligent surgical devices, focusing on integrating AI and robotics into orthopedic instruments [4][5]. - The acquisition of Waterwood Tianpeng Medical Technology Co., Ltd. aims to enhance the company's capabilities in ultrasound energy and active devices, promoting strategic synergies [6]. Group 4: Shareholder Returns and Communication - The company maintains a sustainable dividend strategy, planning to distribute a total cash dividend of 1.1671 million yuan and a capital reserve increase of 2 shares for every 10 shares held [7][8]. - The company emphasizes transparent communication with investors, utilizing various channels to ensure timely and accurate information dissemination [9][10]. Group 5: Governance and Compliance - The company adheres to strict governance standards, ensuring a well-defined structure among shareholders, the board, and management to protect shareholder interests [12][13]. - Continuous training and communication with key personnel are implemented to enhance compliance awareness and operational effectiveness [13][14].